Search

everythinglearnresearchcommunity

for

Search:↓

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.

New compounds were made that block an enzyme linked to breast cancer better than existing treatments.

MT-DADMe-ImmA can selectively kill head and neck cancer cells without harming normal cells.

The drug combination was safe and showed promise in treating advanced tumors.

A new compound, 3a, effectively fights prostate cancer better than finasteride.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.

CDK4/6 inhibitors can protect hair cells from chemotherapy damage.

MK-5108 is safe and shows potential against tumors, especially alone.

PROTACs show promise in cancer treatment by effectively degrading specific harmful proteins.

XMU-MP-1 stops cell growth in a human mini-organ and reduces the effectiveness of the chemotherapy drug paclitaxel.

Blocking mTORC1 reduces skin tumor growth in mice.

Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.

Certain inhibitors slow down plant growth by causing early cell specialization without changing the cell development pattern.

Certain inhibitors applied to the skin can promote hair growth by maintaining a key hair growth signal.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

TICE salvage chemotherapy is effective for treating germ-cell tumors with poor prognosis.

TS-13 effectively stops tumor growth and reduces chemotherapy side effects.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.

Using CDK inhibitors on rats showed a reduction in chemotherapy-caused hair loss, but later experiments could not repeat these results.

The compound 4c showed strong potential as an anticancer agent.

PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.

Topical IKKα inhibitors may help prevent CCS tumours.

New molecules can prevent cell death in hair follicles.

ZSYY001 is safe, well-tolerated, and shows promise for treating advanced solid tumors.

SCD-153 shows promise as an effective topical treatment for alopecia areata.